Aziyo Biologics Announces $14.0 Million Private Placement
06 December 2021 - 10:59PM
Aziyo Biologics, Inc. (the “Company”) today announced that it has
entered into a definitive agreement to sell securities in a private
placement that is expected to result in gross proceeds to the
Company of approximately $14.0 million, before deducting offering
expenses.
Certain accredited investors have agreed to purchase an
aggregate of 2,122,637 shares of the Company’s Class A common stock
and 1,179,244 shares of the Company’s Class B common stock, in each
case, at a price of $4.24 per share. The closing of the offering is
subject to certain conditions and is expected to occur on December
8, 2021.
The offer and sale of the foregoing securities are being made in
a transaction not involving a public offering and have not been
registered under the Securities Act of 1933, as amended (the
“Securities Act”), or applicable state securities laws, and will be
sold in a private placement pursuant to Regulation D of the
Securities Act. The securities being issued in the private
placement may not be offered or sold in the United States absent
registration or pursuant to an exemption from the registration
requirements of the Securities Act and applicable state securities
laws. The Company has agreed to file a registration statement
covering the resale of the shares of Class A common stock acquired
by, or shares of Class A common stock issuable upon conversion of
shares of Class B common stock acquired by, the investors in the
private placement.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the securities, nor shall there be
any sale of the securities in any state in which such offer or sale
would be unlawful prior to the registration or qualification under
the securities laws of such state. Any offering of the securities
under the resale registration statement will only be by means of a
prospectus.
Forward-Looking StatementsAny statements in
this press release about the future expectations, plans and
prospects of the Company, including without limitation, statements
relating to the closing of and the amount of any proceeds from the
private placement transaction, and other statements containing the
words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “would,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors
discussed in the “Risk Factors” section of the Company’s Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission, or SEC, on November 10, 2021, and in other filings that
the Company makes with the SEC. In addition, any forward-looking
statements included in this press release represent the Company’s
views only as of the date of its publication and should not be
relied upon as representing its views as of any subsequent date.
The company specifically disclaims any obligation to update any
forward-looking statements included in this press release.
Contact Information:Courtney GuyerAziyo
Biologics, Inc.PR@aziyo.com
Leigh SalvoGilmartin Groupinvestors@aziyo.com
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aziyo Biologics (NASDAQ:AZYO)
Historical Stock Chart
From Apr 2023 to Apr 2024